Patents by Inventor Zibo Zhao

Zibo Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF NUCLEOTIDE SYNTHESIS INHIBITORS FOR TARGETED THERAPY IN MLL3/4 COMPASS MUTANT CANCER
    Publication number: 20230390297
    Abstract: Disclosed herein are methods and compositions for treating a subject comprising the administration of an effective amount of a nucleotide synthesis inhibitor to a subject in need of treatment for a MLL3/4 COMPASS deficient cancer or a MLL3/4 loss of function mutation.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Inventors: Ali Shilatifard, Zibo Zhao
  • Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
    Patent number: 11071727
    Abstract: Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: July 27, 2021
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Zibo Zhao
  • Conferencing system including a remote microphone and method of using the same
    Patent number: 10469667
    Abstract: A conferencing system and method are disclosed. An exemplary system includes a conference device and one or more user devices. The conference device is configured to receive audio information from one or more user devices. The audio information received by the conference device can be mixed with audio information received by conference device microphones.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 5, 2019
    Assignee: MITEL NETWORKS CORPORATION
    Inventors: Zibo Zhao, Anjie Wu
  • THERAPEUTIC TARGETING OF PROTEOLYTIC CLEAVAGE OF THE MIXED LINEAGE LEUKEMIA GENE PRODUCT (MLL1) BY TASPASE1 USING KINASE INHIBITORS
    Publication number: 20190231759
    Abstract: Disclosed are methods and pharmaceutical compositions for treating a cancer in a subject in need thereof, the cancer characterized by proteolytic cleavage by taspase1 of the mixed-lineage leukemia 1 gene product (MLL1), the method comprising administering to the subject a therapeutic agent that inhibits cleavage by taspase1 of MLL1. Suitable therapeutic agents may include agents that inhibit the kinase activity of casein kinase II (CKII). Cancer treated by the disclosed methods and pharmaceutical compositions may include leukemia such as Acute Lymphoblastic Leukemia (ALL) and/or Acute Myeloid Leukemia (AML) and in particular, leukemia characterized by rearrangements in MLL1.
    Type: Application
    Filed: January 25, 2019
    Publication date: August 1, 2019
    Applicant: Northwestern University
    Inventors: Ali Shilatifard, Zibo Zhao
  • Conferencing System Including a Remote Microphone and Method of Using the Same
    Publication number: 20150201082
    Abstract: A conferencing system and method are disclosed. An exemplary system includes a conference device and one or more user devices. The conference device is configured to receive audio information from one or more user devices. The audio information received by the conference device can be mixed with audio information received by conference device microphones.
    Type: Application
    Filed: January 14, 2014
    Publication date: July 16, 2015
    Inventors: Zibo Zhao, Anjie Wu